New Combination Chemotherapy for Colorectal Cancer

Last week, the U.S. Food and Drug Administration (FDA) approved a new combination of drugs, formulated together in a single pill called Lonsurf (previously known as TAS-102), to treat patients with advanced colorectal cancer that is no longer responding to other treatments after the treatment was shown in a double-blind, placebo-controlled, phase III clinical trial to extend overall survival.

Read More

From the Journals: Progress Against Colorectal Cancer Lags in Three Large U.S. “Hot Spots”

While most of the United States has experienced large declines in colorectal cancer death rates in recent years, progress in three large “hot spots” has lagged, according to a study …

Read More

From the Journals: Fear May Reduce Colorectal Cancer Screening Uptake

A recent study in the AACR’s journal Cancer Epidemiology, Biomarkers & Prevention suggests that different types of cancer fear have different effects on people, and a type of fear may be keeping people from getting necessary colorectal cancer screenings.

Read More

Dutch-American Research Team Aiming to Improve Colorectal Cancer Screening

Despite current screening efforts, colorectal cancer is the fourth most commonly diagnosed cancer worldwide and the fifth leading cause of cancer-related death. A newly formed trans-Atlantic team of researchers brought together by Stand Up To Cancer (SU2C) and the Dutch Cancer Society, KWF Kankerbestrijding (KWF), is hoping to change this by developing a new molecular test for stool-based colorectal cancer screening.

Read More